Drug design, development and therapy · 2025
Prospective Single-Arm Study of Remifentanil-Propofol Anesthesia with Manual Right Hypochondrial Compression for Painless Gastroscopy in Obese Patients.
СтатьяКлиническое исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wang Mengxia, Tang Jieke, Pan Zhaojie, Jiang Hongxue, Hu Donghua, Zhu Beibei, Liang Zhaojia, Zhao Xiangfeng, Li Yalan
Аннотация
PURPOSE: The provision of comfortable and safe environment for painless gastroscopy in obese patients is an urgent clinical problem. This study aimed to determine the efficacy and safety of the novel Li anesthetic protocol for obesity (LAPO) which included remifentanil-propofol regimen, manual right hypochondrial compression (MRHC), easy-to-create mask, and jaw thrust at preoperative painless gastroscopy in obese patients.
PATIENTS AND METHODS: This prospective, single-center, single-arm trial recruited 106 participants underwent LAPO for gastroscopy. The primary outcome was the incidence of hypoxemia (peripheral oxygen saturation [SpO2]: 75% ≤ SpO2 <90%, for >10 s and ≤60 s). Second outcomes included severe hypoxemia, the lowest SpO2 (L-SpO2), duration of hypoxemia, and other events.
RESULTS: The 98 obese patients under LAPO, the median body mass index (BMI) was 39.2 kg/m2 and the incidence of hypoxemia was 27.5%, while the conventional anesthetic protocol for obesity (CAPO) in the reference was 40.4% with BMI 31.4 kg/m2. With the increase of class of obesity, a significant rise in the incidence of hypoxemia was observed, from class I by 11.8%, to 15.1% in class II, and 41.7% in class III. Paired t test showed that the L-SpO2 was significantly higher than L-SpO2 in overnight polysomnography (Nadir SpO2) (92% vs 76%, P<0.001). Moreover, severe obstructive sleep apnea (OSA) was associated with a 4.019-fold higher risk of hypoxemia (Odds ratios [OR], 4.019; 95% confidence interval [CI], 1.184 to 14.610; P=0.028); diabetes was associated with a 4.790-fold higher risk of hypoxemia (OR, 4.790; 95% CI, 1.288 to 23.600; P=0.030).
CONCLUSION: Compared with CAPO, LAPO reduced the incidence of hypoxemia from 40.4% to 27.5%, so, LAPO was safe and effective for painless gastroscopy. The finding might provide some new schedules for anesthetic management in the absence of advanced airway support instruments.
CLINICAL TRIAL REGISTRATION: ChiCTR2300077889.
PATIENTS AND METHODS: This prospective, single-center, single-arm trial recruited 106 participants underwent LAPO for gastroscopy. The primary outcome was the incidence of hypoxemia (peripheral oxygen saturation [SpO2]: 75% ≤ SpO2 <90%, for >10 s and ≤60 s). Second outcomes included severe hypoxemia, the lowest SpO2 (L-SpO2), duration of hypoxemia, and other events.
RESULTS: The 98 obese patients under LAPO, the median body mass index (BMI) was 39.2 kg/m2 and the incidence of hypoxemia was 27.5%, while the conventional anesthetic protocol for obesity (CAPO) in the reference was 40.4% with BMI 31.4 kg/m2. With the increase of class of obesity, a significant rise in the incidence of hypoxemia was observed, from class I by 11.8%, to 15.1% in class II, and 41.7% in class III. Paired t test showed that the L-SpO2 was significantly higher than L-SpO2 in overnight polysomnography (Nadir SpO2) (92% vs 76%, P<0.001). Moreover, severe obstructive sleep apnea (OSA) was associated with a 4.019-fold higher risk of hypoxemia (Odds ratios [OR], 4.019; 95% confidence interval [CI], 1.184 to 14.610; P=0.028); diabetes was associated with a 4.790-fold higher risk of hypoxemia (OR, 4.790; 95% CI, 1.288 to 23.600; P=0.030).
CONCLUSION: Compared with CAPO, LAPO reduced the incidence of hypoxemia from 40.4% to 27.5%, so, LAPO was safe and effective for painless gastroscopy. The finding might provide some new schedules for anesthetic management in the absence of advanced airway support instruments.
CLINICAL TRIAL REGISTRATION: ChiCTR2300077889.